<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Perry MD</submitter><funding>Roche Molecular Systems</funding><pagination>43-52</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9816248</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>42(1)</volume><pubmed_abstract>Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) can lead to long-term sequelae in males and females; however, global prevalence data vary between geographical regions, as these sexually transmitted infections are not included in routine screening. The objective of this study was to use the cobas&lt;sup>®&lt;/sup> TV/MG assay to assess the point prevalence of TV and MG in specimens from men and women over a broad European geographical area. Urine, vaginal, endocervical, and rectal samples were collected from patients aged ≥ 18 years receiving Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) screening as per local standard of care at sites in Belgium, Germany, Spain, and the UK (Wales). Remnant samples were assessed using the cobas TV/MG assay. Analysis of 2795 samples showed that MG prevalence varied slightly across female sample types (range: 1.7-5.8%; p = 0.0042). MG prevalence was higher in male rectal samples (12.5%) than in male urine samples (3.9%; p &lt; 0.0001). TV prevalence was low in male (0.8%; 12/1535) and female (1.3%; 16/1260) samples across all sites. Co-infection of TV/MG with CT or NG was 10.0% (19/190) and 9.6% (7/73), respectively, in both male and female samples. MG and TV prevalence rates were comparable to the published literature in Europe. MG prevalence was highest in male rectal samples; as rectal testing is an off-label use of the cobas TV/MG assay, the clinical utility of this assay for rectal testing should be further investigated.</pubmed_abstract><journal>European journal of clinical microbiology &amp; infectious diseases : official publication of the European Society of Clinical Microbiology</journal><pubmed_title>The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay.</pubmed_title><pmcid>PMC9816248</pmcid><funding_grant_id>Study number: RD003557</funding_grant_id><pubmed_authors>de Salazar A</pubmed_authors><pubmed_authors>Schiettekatte G</pubmed_authors><pubmed_authors>Hansra A</pubmed_authors><pubmed_authors>Bertram A</pubmed_authors><pubmed_authors>Njoya M</pubmed_authors><pubmed_authors>Garcia F</pubmed_authors><pubmed_authors>Barrientos-Duran A</pubmed_authors><pubmed_authors>Lewinski M</pubmed_authors><pubmed_authors>Perry MD</pubmed_authors><pubmed_authors>Arcenas R</pubmed_authors><pubmed_authors>Jones S</pubmed_authors></additional><is_claimable>false</is_claimable><name>The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay.</name><description>Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) can lead to long-term sequelae in males and females; however, global prevalence data vary between geographical regions, as these sexually transmitted infections are not included in routine screening. The objective of this study was to use the cobas&lt;sup>®&lt;/sup> TV/MG assay to assess the point prevalence of TV and MG in specimens from men and women over a broad European geographical area. Urine, vaginal, endocervical, and rectal samples were collected from patients aged ≥ 18 years receiving Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) screening as per local standard of care at sites in Belgium, Germany, Spain, and the UK (Wales). Remnant samples were assessed using the cobas TV/MG assay. Analysis of 2795 samples showed that MG prevalence varied slightly across female sample types (range: 1.7-5.8%; p = 0.0042). MG prevalence was higher in male rectal samples (12.5%) than in male urine samples (3.9%; p &lt; 0.0001). TV prevalence was low in male (0.8%; 12/1535) and female (1.3%; 16/1260) samples across all sites. Co-infection of TV/MG with CT or NG was 10.0% (19/190) and 9.6% (7/73), respectively, in both male and female samples. MG and TV prevalence rates were comparable to the published literature in Europe. MG prevalence was highest in male rectal samples; as rectal testing is an off-label use of the cobas TV/MG assay, the clinical utility of this assay for rectal testing should be further investigated.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-05-29T16:21:56.559Z</modification><creation>2025-04-04T20:33:15.077Z</creation></dates><accession>S-EPMC9816248</accession><cross_references><pubmed>36369413</pubmed><doi>10.1007/s10096-022-04521-5</doi></cross_references></HashMap>